INTRODUCTION
============

Gastroesophageal reflux disease (GERD) is a condition that develops when reflux of gastric contents into the esophagus leads to mucosal damage and its sequelae. The incidence of GERD is estimated to be 10--20% in Western countries, making it one of the most prevalent gastrointestinal disorders ([@b8-bt-22-420]). The existing therapeutic strategy for GERD is aimed primarily at reducing gastric acidity by the administration of anti-secretory agents such as H~2~ receptor antagonists and proton pump inhibitors (PPIs). Despite their well-known efficacy, a number of patients have experienced relapse, incomplete mucosal healing or ensuing complications, suggesting the involvement of targets other than acid secretion in the pathogenesis of reflux esophagitis (RE) ([@b15-bt-22-420]).

The development of RE is more consistent with immune-mediated injury than with injury caused by the toxic effects of acid, emphasizing the orchestration of chemokine and cytokine secretion and inflammatory cell migration, including T cell and neutrophils ([@b30-bt-22-420]). An imbalance in the generation of free radicals, especially reactive oxygen species (ROS), and cellular antioxidant capacity leads to a state of oxidative stress, which is also critical in the etiology of RE in both animals and human subjects ([@b34-bt-22-420]; [@b35-bt-22-420]). ROS contributes to esophageal inflammation, and ROS produced by inflammatory and epithelial cells accelerate RE resulting in Barrett's esophagus and adenocarcinoma ([@b1-bt-22-420]). Thus, therapeutic agents possessing the properties to scavenge ROS and modulate inflammatory response might exert significant effects in attenuating tissue injury by RE.

The application of natural products that regulate redox state and inflammation has emerged for GERD treatment. For example, an ethanol extract of *Artemisia asiatica* was reported to prevent RE through its antioxidant properties *in vivo*, ([@b21-bt-22-420]) and a phytopharmaceutical derived from *A. asiatica* has been prescribed for gastritis patients in S. Korea ([@b27-bt-22-420]). Chlorogenic acid (CGA), formed by the esterification of caffeic acid and quinic acid, is one of the most abundant polyphenols in the human diet ([@b11-bt-22-420]; [@b5-bt-22-420]). Numerous studies based on *in vivo* and *in vitro* experiments show that CGA has antioxidant, antibacterial and anti-carcinogenic activities ([@b2-bt-22-420]; [@b26-bt-22-420]). Moreover, we previously reported the protective effects of CGA against experimental inflammatory disorders: CGA inhibited high mobility group box 1 release and toll-like receptor 4 signaling pathways in liver during both septic and ischemic insult, suggesting its potential in immunomodulation ([@b17-bt-22-420]; [@b37-bt-22-420]). Most recently, CGA was shown to suppress HCl/ethanol- and piroxicam-induced gastric mucosal injury ([@b29-bt-22-420]) while its high absorption capacity to gastric and intestinal cells by oral route is focused ([@b9-bt-22-420]; [@b31-bt-22-420]). However, the effects of CGA on RE have not been studied.

In this study, we investigate the protective effects and molecular mechanisms of CGA in a surgically-induced rat model of RE, with particular attention to antioxidant and anti-inflammatory properties.

MATERIALS AND METHODS
=====================

Chemicals and antibodies
------------------------

CGA was purchased from Sigma-Aldrich (St. Louis, MO, USA). The following antibodies were used in this study: inducible nitric oxide synthase (iNOS; Transduction Laboratories, San Jose, CA, USA), cyclooxygenase-2 (COX-2; Cayman, Ann Arbor, MI, USA) and β-actin antibody (Sigma-Aldrich).

Animals
-------

All animals received care in compliance with the Principles of Laboratory Animal Care formulated by the National Institutes of Health (NIH publication No.86-23, revised 1985) and the guidelines of the Sungkyunkwan University Animal Care Committee. Male SD rats weighing 180 to 200 g were obtained from Orient Bio Inc. (Seongnam, Korea) and were acclimatized to laboratory conditions for at least one week. Rats were maintained in a room with controlled temperature and humidity (25 ± 1°C and 55 ± 5%, respectively) with a 12 h light-dark cycle.

RE induction and drug treatment
-------------------------------

All rats were fasted for 24 h prior to surgical procedures, but were provided with tap water *ad libitum*. Surgical procedures were performed under general anesthesia, which was accomplished by intraperitoneal injections of ketamine (55 mg/kg) and xylazine (7 mg/kg). The pyloric stenosis model ([@b22-bt-22-420]) was used, and the duodenum near the pylorous was wrapped with a piece of Nélaton catheter (width, 3.0 mm; Camel^®^, Dae Bo Co., GwangJu, Korea) as a ring. The diameter of each Nélaton catheter was 4.0 mm and the ring was surrounded and tied with 3-0 silk thread to prevent dislodgement. The transitional region between the forestomach and the glandular portion (the limiting ridge) was ligated with 3-0 silk thread. The sham operation induced a midline laparotomy alone without further surgical interventions. After preparation of the model, the animals were deprived of food for 48 h but were allowed free access to drinking water. Two days after the surgery, vehicle or drugs were administered for 12 days. After the final treatment, rats were fasted for 24 h and sacrificed. The entire esophagus was removed and examined for gross mucosal injury. The esophageal tissue was immediately frozen in liquid nitrogen and stored at −80°C for the biochemical assays.

Experimental groups
-------------------

All drugs were administered orally. Rats were divided into 6 groups as follows (n=8--10 rats per group). Group I: vehicle-treated sham animals (sham); Group II: vehicle-treated RE animals (control); Group III-V: CGA 10, 30 and 100 mg/kg (dissolved in saline)-treated RE animals (CGA 10, 30 and 100 mg/kg); Group VI: omeprazole 10 mg/kg (dissolved in 0.5% methylcellulose (MC)-distilled water (DW))-treated RE animals (Omp 10 mg/kg). In vehicle-treated rats, saline or 0.5% MC-DW was administered in the same volume and manner as the respective reagents. No effects of these vehicles on esophagus function were detected. The dose range of the drugs and the time of administration were chosen based on previous reports ([@b19-bt-22-420]; [@b29-bt-22-420]) and our preliminary studies.

Esophageal lesion score
-----------------------

The esophageal tissues were washed with physiological saline and photographs were taken of specified areas of damage. The width of the damaged esophagitis area (mm^2^) was determined and defined as the lesion score.

Hematoxylin and eosin staining
------------------------------

Formalin-fixed samples were embedded in paraffin and cut into 5-μm sections. Tissues were stained with hematoxylin and eosin (H&E), and slides were assessed for inflammation and tissue damage using Olympus microscopes (OLYMPUS OPTICAL Co., Tokyo, Japan) at 200× magnification.

Gastric content pH
------------------

The gastric contents were obtained from the stomach and centrifuged at 3,000 *g* for 20 min. The supernatant was assessed for pH (Toledo 320, Mettler, Switzerland).

Lipid peroxidation and GSH/GSSG ratio
-------------------------------------

The steady-state level of malondialdehyde (MDA), which is the end-product of lipid peroxidation, was determined in the esophageal tissues by measuring the levels of thiobarbituric acid-reactive substances ([@b4-bt-22-420]). The total esophageal glutathione level was determined by measuring yeast-glutathione reductase, 5,5′-dithio-bis(2-nitrobenzoic acid), and nicotinamide adenine dinucleotide phosphate (NADPH) in the esophagus homogenates after precipitation with 1% picric acid. The level of oxidized glutathione (GSSG) was determined using the same method but in the presence of 2-vinylpyridine. The reduced glutathione (GSH) level was calculated as the difference between the total glutathione and the GSSG level ([@b12-bt-22-420]).

Serum TNF-α
-----------

The serum TNF-α level was quantified by enzyme-linked immunosorbent assay (ELISA) using a commercial TNF-α ELISA assay kit (BD Biosciences Co., SanJose, CA, USA) according to the manufacturer's instructions.

Western blot analysis for iNOS and COX-2
----------------------------------------

Esophageal tissue protein lysates were prepared using radioimmunoprecipitation assay buffer, separated on SDS-PAGE gels, and transferred to polyvinylidenedifluoride membranes as previously described ([@b32-bt-22-420]). Western blotting was performed using primary antibodies and horse-radish peroxidase-conjugated secondary antibodies suitable for each parameter. The WEST-one Western Blot Detection System (iNtRON Biotechnology Inc., Seongnam, Korea) was used for detection according to the manufacturer's instructions. Intensities of the immunoreactive bands were determined using TotalLab TL120 software (IVDLab Nonlinear Dynamics Co. Ltd., Newcastle, UK). β-Actin was used as a loading control and the levels of proteins were normalized with respect to β-actin band intensity.

Statistical analysis
--------------------

All results are presented as the mean ± S.E.M. The overall significance of the data was tested by one-way analysis of variance using the SPSS v.12.0 statistical software package (SPSS, Chicago, IL, USA). Differences between groups were considered statistically significant at *p*\<0.05 with appropriate Bonferroni corrections made for multiple comparisons.

RESULTS
=======

Esophageal lesion scores
------------------------

Sham-operated rats showed normal esophageal tissue. The esophageal lesion score (mm^2^) of the RE control group was 44.2 ± 3.6. CGA at 10 mg/kg showed a tendency to attenuate the lesion score to 20.9 ± 7.7. CGA at 30 and 100 mg/kg attenuated the lesion score to 19.6 ± 2.8 and 17.0 ± 3.9, respectively. Omeprazole at 10 mg/kg also attenuated the lesion score to 14.4 ± 5.5 ([Fig. 1A](#f1-bt-22-420){ref-type="fig"}).

Gastric content pH
------------------

The gastric content pH of the RE control group was 2.2 ± 0.1, which was similar to that of sham-operated rats. CGA at 10, 30 and 100 mg/kg did not affect the gastric content pH (2.1 ± 0.2, 2.4 ± 0.3, and 2.2 ± 0.3, respectively). However, omeprazole at 10 mg/kg increased the pH to 3.6 ± 0.6 ([Fig. 1B](#f1-bt-22-420){ref-type="fig"}).

Histological observations
-------------------------

The representative pathological observations are shown in [Fig. 1C](#f1-bt-22-420){ref-type="fig"}. After RE induction, severe inflammatory cell infiltrations with large excavated ulcerations were observed. Moreover, RE caused marked thickening of the esophageal epithelium, elongation of lamina propria papillae and basal cell hyperplasia. However, both CGA at 30 mg/kg and omeprazole at 10 mg/kg attenuated these changes.

Lipid peroxidation and GSH/GSSG ratio
-------------------------------------

In the sham group, the level of MDA was 0.2 ± 0.1 nmol/mg protein. Following RE treatment, the level of MDA increased significantly, to 1.6 ± 0.1 nmol/mg protein, compared with the sham. CGA at a concentration of 30 mg/kg was found to attenuate this increase in MDA level (0.8 ± 0.1 nmol/mg protein). The GSH/GSSG ratio in the sham group was 21.1 ± 0.3. After RE treatment, the GSH/GSSG ratio significantly decreased to 5.1 ± 0.7, and this decrease was attenuated by 30 mg/kg of CGA ([Fig. 2](#f2-bt-22-420){ref-type="fig"}).

Serum TNF-α concentration
-------------------------

The serum level of TNF-α in the sham group was 11.3 ± 0.2 pg/ml. After RE treatment, the serum level of TNF-α significantly increased to 44.9 ± 2.8 pg/ml, and CGA at 30 mg/kg attenuated this increase (35.9 ± 2.8 pg/ml)([Fig. 3A](#f3-bt-22-420){ref-type="fig"}).

iNOS and COX-2 protein expressions
----------------------------------

The levels of iNOS and COX-2 protein expression significantly increased to 6.9 and 3.0 times the sham value after RE treatment. CGA at 30 mg/kg attenuated these increases, respectively ([Fig. 3B](#f3-bt-22-420){ref-type="fig"}).

DISCUSSION
==========

A number of pathological mechanisms have been suggested to play roles in RE, including hypersensitivity of the esophageal mucosal to physiological reflux, reduced mucosal defense mechanisms, and gastric motility disturbances. A recent study reported that mucosal damage detected in GERD might result from the release of inflammatory mediators from mucosal and sub-mucosal cells in response to bile salts and gastric refluxate ([@b30-bt-22-420]). Since GERD is a multi-factorial disease, it would be plausible to use multi-target drugs for its treatment, and the objective of the treatment should be to restore the balance between aggressive and mucosal protecting factors, rather than simple acid suppression.

Insight into RE treatment has shifted toward studies aimed at the understanding of antioxidant and cytoprotective actions of natural products or bioactive components in the diet. Previously, *Flos Lonicerae* extract, which contains CGA as a major component, increased the activities of endogenous antioxidants including GSH, superoxide dismutase and catalase, and ultimately reduced esophageal damage induced by RE ([@b16-bt-22-420]). CGA, a phenolic compound with anti-inflammatory and antioxidant properties, inhibited lipopolysaccharide-induced inflammatory cytokines release in RAW264.7 cells ([@b28-bt-22-420]). Most recently, CGA inhibited neutrophil migration and restored the levels of antioxidant enzymes in ethanol/HCl- and piroxicam-induced gastric ulcer models, suggesting protective effects against gastrointestinal tract inflammation ([@b29-bt-22-420]). However, the effects and precise mechanisms of CGA in RE have not been studied until now.

Exposure of the esophagus to acid and digestive enzymes found in gastric fluid or duodenal contents regurgitated into the stomach may induce and promote irritation and result in symptoms and morphological changes to the esophageal mucosa ([@b20-bt-22-420]). In the present study, esophagitis was found 2 or 3 cm above the esophagogastric junction, and esophageal lesion scores were remarkable 14 days after RE operation. However, the administration of CGA attenuated the lesion score, suggesting the therapeutic potential of CGA against RE. As typical reflux symptoms are associated with reflux episodes with drops in pH, lower minimum pH and reduced acid clearance times ([@b3-bt-22-420]), we measured the pH of gastric contents. Unexpectedly, CGA did not affect pH level, while omeprazole, an irreversible inhibitor of H^+^, K^+^-ATPase, showed strong effects on gastric content pH, confirming its anti-secretory effects. Our results agree with those of a previous report indicating that CGA does not interfere with gastric secretion or the pH of gastric juices in mice with pyloric ligatures ([@b29-bt-22-420]). Moreover, this characteristic of CGA might supplement the side effects of long term treatment of PPI such as hypochlorhydria or rebound hypersecretion that could lead to PPI-deficiency ([@b24-bt-22-420]).

Inflammatory processes seem to play pivotal roles in the underlying mechanisms of the symptoms and pathogenesis of gastrointestinal conditions including GERD. Particularly in the chronic phase of RE, continuous exposure to acid induces persistent infiltration of inflammatory cells and increases epithelial cell proliferation in the basal layer ([@b14-bt-22-420]). Increased TNF-α and interleukin-6 concentrations have been demonstrated in the esophageal tissues of rats challenged to produce acute RE ([@b6-bt-22-420]; [@b7-bt-22-420]). iNOS, an enzyme catalyzing NO production, is also upregulated during the development of Barrett's esophagus and adenocarcinoma, and its expression may be stimulated by cytokines such as TNF-α during mucosal inflammation and tumor progression ([@b36-bt-22-420]). In addition, COX-2 producing PGE~2~ were colocalized in epithelial cells of the basal layer, as well as inflammatory and mesenchymal cells in the lamina propria and submucosa exposed to acid re-flux. COX-2 inhibitors such as celecoxib significantly reduced the severity of chronic esophagitis ([@b13-bt-22-420]). Nuclear factor-kappa B, mitogen-activated protein kinases and protein kinase C activation are known to be involved in the regulation of acid-induced upregulation of these inflammatory mediators *in vitro* ([@b23-bt-22-420]). In the present study, serum levels of TNF-α and iNOS and COX-2 protein expressions in esophageal tissues were increased by RE, and CGA attenuated these increases. These results indicate that the esophagoprotection by CGA might be attributable to its anti-inflammatory properties.

Oxygen-derived free radicals in RE induced esophageal mucosal damage resulting in mucosal inflammation and to control free radical generation, such as superoxide dismutase administration, inhibited the incidence of RE ([@b33-bt-22-420]). Increased production of oxygen-derived free radicals was accompanied by enhanced esophageal mucosal lipid peroxidation, which is a sensitive marker of membrane damage caused by free radicals ([@b10-bt-22-420]). This is evident from our results showing significant increases in the levels of lipid peroxidation in RE rats. In addition, thiol containing glutathione is an important non-enzymatic antioxidant, which promotes several toxic metabolites. The gastric mucosa contains high amounts of glutathione, which is vital for the maintenance of mucosal integrity, since depletion of GSH from the gastric mucosa by electrophilic compounds induces mucosal ulceration ([@b18-bt-22-420]). Exogenous thiol compounds have been suggested to protect the stomach from ethanol-induced necrosis ([@b25-bt-22-420]). In the present study, decreases in the GSH/GSSG ratio were observed in RE-induced rats. CGA not only inhibited lipid peroxidation but increased the GSH/GSSG ratio. In summary, our results signify that CGA could act not only as a direct free radical scavenger but also enhance esophageal defense mechanisms to minimize esophageal inflammation.

In conclusion, CGA promotes regression of RE through the down-regulation of inflammatory response, possibly due to its antioxidant capacity. CGA can serve as an alternative treatment and/or in combination with the anti-secretory regimen to alleviate the severity of RE.
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![Effects of CGA on esophageal damage, gastric content pH and histological observations in RE. (A) The esophageal lesion score was determined by the width of the damaged esophagitis area (mm^2^). Scale bar, 1 cm. (B) The pH of the gastric contents from the stomach was measured. (C) Representative photomicrographs of H&E stained sections are shown (original magnification×200). RE control animals showed inflammatory cell infiltrations and edema (arrows heads); CGA 30 mg/kg- and omeprazole 10 mg/kg-treated RE animals showed attenuation of pathological changes. Arrow indicates mild thickening of the esophageal epithelium. Scale bar, 50 μm. Results are presented as mean ± S.E.M. of 8--10 animals per group. ^†,††^Denote significant differences (*p*\<0.05, *p*\<0.01), compared with the control group.](bt-22-420f1){#f1-bt-22-420}

![Effects of CGA on oxidative stress in RE. The level of MDA (A), a marker of lipid peroxidation, and GSH/GSSG ratio (B) were respectively measured in esophageal tissue. Results are presented as mean ± S.E.M. of 8--10 animals per group. ^\#\#^Denotes significant differences (*p*\<0.05, *p*\<0.01), compared with the sham group; ^†,††^De note significant differences (*p*\<0.05, *p*\<0.01), compared with the control group.](bt-22-420f2){#f2-bt-22-420}

![Effects of CGA on inflammatory mediators in RE. (A) The serum concentration of TNF-α was determined using an enzyme-linked immunosorbent assay. (B) Western blot analysis for iNOS and COX-2 was performed on whole extracts from the esophagus. Results are presented as mean ± S.E.M. of 8--10 animals per group. ^\#,\#\#^Denote significant differences (*p*\<0.05, *p*\<0.01), compared with the sham group; ^†,††^Denote significant differences (*p*\<0.05, *p*\<0.01), compared with the control group.](bt-22-420f3){#f3-bt-22-420}
